BCL7A anticorps (Middle Region)
Aperçu rapide pour BCL7A anticorps (Middle Region) (ABIN632338)
Antigène
Voir toutes BCL7A AnticorpsReactivité
Hôte
Clonalité
Conjugué
Application
-
-
Épitope
- Middle Region
-
Specificité
- BCL7 A antibody was raised against the middle region of BCL7
-
Purification
- Affinity purified
-
Immunogène
- BCL7 A antibody was raised using the middle region of BCL7 corresponding to a region with amino acids QENSSNSSPAPEPNSAVPSDGTEAKVDEAQADGKEHPGAEDASDEQNSQS
-
-
-
-
Indications d'application
-
WB: 1 µg/mL
Optimal conditions should be determined by the investigator. -
Commentaires
-
BCL7A Blocking Peptide, (ABIN5612307), is also available for use as a blocking control in assays to test for specificity of this BCL7A antibody
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Reconstitution
- Lyophilized powder. Add distilled water for a 1 mg/mL concentration of BCL0 antibody in PBS
-
Concentration
- Lot specific
-
Buffer
- PBS
-
Conseil sur la manipulation
-
Avoid repeated freeze/thaw cycles.
Dilute only prior to immediate use. -
Stock
- 4 °C/-20 °C
-
Stockage commentaire
- Store at 2-8 °C for short periods. For longer periods of storage, store at -20 °C.
-
-
- BCL7A (B-Cell CLL/lymphoma 7A (BCL7A))
-
Autre désignation
- BCL7A
-
Sujet
- This gene is directly involved, with Myc and IgH, in a three-way gene translocation in a Burkitt lymphoma cell line. As a result of the gene translocation, the N-terminal region of the gene product is disrupted, which is thought to be related to the pathogenesis of a subset of high-grade B cell non-Hodgkin lymphoma.
-
Poids moléculaire
- 25 kDa (MW of target protein)
Antigène
-